Strategic Vaccine &
mRNA Pipeline Review
The most comprehensive independent analysis of the global industry vaccine and mRNA clinical trial landscape - 2,178 Phase I-IV trials, 104 pathogens, 270 companies. Now with 70 verified active programmes from 8 large developers, refreshed October 2026, and a dedicated mRNA landscape focus section.
- Previous edition
- VAMV084A (June 2026)
- Format
- MS Excel workbook
- Trials covered
- 2,178
- Verified active programmes
- 70 (8 developers)
- Pipeline refresh
- October 2026
- Companies
- ~270
- Pathogens
- 104
- Market segments
- 16
- Data start date
- Jan 2014
Phase I-IV
companies
conditions
trials identified
segments
Explore the verified pipeline yourself
Compare the large developers at a glance, then filter every verified active programme by phase, pathogen and segment, or play the tracker to see how the pipeline has grown since 2021. Programme status is as verified in October 2026.
Twelve layers of analysis in one workbook
Each trial has been curated and annotated with new fields that go far beyond the raw ClinicalTrials.gov export - enabling market-ready competitive intelligence outputs.
Dedicated mRNA and DNA scan across all trials. Platform identification by company tier, market segment and pathogen. saRNA/replicon programmes flagged separately.
104 pathogens ranked by trial volume (completed + ongoing). New vs. existing segment designation. Coverage spans infectious disease, oncology and chronic conditions.
16 segments including COVID-19, Novel, Oncology, Influenza, RSV, Pediatric, Travel/endemic, Pneumococcal. Volume and nucleic acid penetration by segment.
Small (<$100m), Medium ($100-500m) and Large (>$500m vaccine revenues/yr) developer tiers. 37 large, 16 medium, 200+ small companies catalogued.
19 vaccine platform types classified per programme - from mRNA to polysaccharide conjugates. Adjuvantation status and adjuvant type captured for verified programmes.
Curated list of 70 confirmed active programmes from 8 large developers (Phase 1 to Phase 3, refreshed October 2026) - separate from raw trial registry data. Expert-audited with source references and a change log since May 2026.
The mRNA vaccine pipeline - identified, classified, ranked
This edition includes the most comprehensive independent tracking of mRNA vaccine programmes across all disease areas - not just COVID-19. The analysis identifies emerging seasonal influenza combinations, RSV pipelines and non-infectious disease applications in oncology. Of the 70 verified active programmes, 38 are nucleic-acid based (mRNA, mRNA neoantigen or saRNA), led by Moderna (15), BioNTech (8), Pfizer (5) and Sanofi (5).
mRNA trials identified by title scan (Phase I-IV, industry only, data cut 22 October 2026)
Key programmes tracked (October 2026 status)
- ModernamRNA-1010 Seasonal influenza Phase 3
- ModernamRNA-1403 Norovirus Phase 3
- ModernamRNA-1018 Pandemic influenza Phase 3
- ModernamCOMBRIAX Flu/COVID-19 combination Licensed
- BioNTechBNT161 Influenza Phase 3
- MSDV940 mRNA neoantigen, melanoma and NSCLC Phase 3
- PfizerPF-07252220 Influenza mRNA, plus PF-07845104 saRNA
- GSKGSK4382276 Influenza mRNA
- SanofiSP0289 Pandemic (H5) influenza mRNA
- BioNTechBNT166 Mpox mRNA
Plus the remaining nucleic-acid programmes, discontinued candidates and oncology-focused mRNA neoantigen programmes - full universe covered in the workbook. Explore them interactively.
104 pathogens ranked - from COVID-19 to rare biodefense agents
Every pathogen and condition is ranked by trial volume and categorised by new vs. existing vaccine. A sample of the coverage is shown below - the full ranked list is in the workbook.
Tags sized by trial volume. Gold = oncology. Full ranked list with trial counts, new/existing designation and market segment in the workbook.
A glimpse of the pipeline - by pathogen and market segment
The table below shows a partial view of the pathogen-level breakdown. The full workbook contains 9 linked summary sheets, ranked tables, nucleic acid analysis and company-level breakdowns across all 16 segments.
| Rank | Pathogen / Condition | Trials (Ph I-IV) | New vaccine? | Market segment | mRNA trials |
|---|---|---|---|---|---|
| 1 | COVID-19 | 386 | New | COVID-19 | 88 |
| 2 | Influenza | 259 | Existing | Influenza | 38 |
| 3 | Respiratory Syncytial Virus | 153 | New | RSV | 21 |
| 4 | Pneumococcal | 135 | Existing | Pneumococcal | 0 |
| 5 | Meningococcal Infections | 91 | Existing | Meningococcal | 0 |
| 6 | ████████████████ | ██ | ███ | █████████ | ██ |
| 7 | ███████████ | ██ | ████████ | █████ | ██ |
| 8 | ██████████████████ | ██ | Existing | ████████ | █ |
| 9 | ████████ | ██ | ███ | ████████████ | ██ |
| 10 | ██████████ | ██ | ███ | ████████ | █ |
What you receive
The licensed workbook is a self-contained intelligence tool - not a flat data dump. All summary sheets are formula-driven and cross-linked.
- MS Excel workbook (.xlsb) - fully formula-driven, 40+ linked worksheets covering all analysis dimensions
- Industry trials master dataset - 2,178 trials with 27 annotated fields per trial including company type, platform, market segment and duration
- 9 summary analysis sheets - pathogen ranking, market segment breakdown, nucleic acid landscape, company-level mRNA/DNA, platform type distribution and more
- mRNA landscape section - company-level mRNA programme counts, platform classification, saRNA identification and non-ID/oncology focus
- Verified active programme list - expert-audited list of 70 confirmed pipeline programmes from 8 large developers with phase, segment, platform type, adjuvantation status and source references, plus the October 2026 change log
- Company analysis - Large (37 companies), Medium (16), Small (200+) developer tiers with COUNTIF-ready company lists
- Interactive pipeline explorer - preview it online before you license
- Access to an executive presentation - PowerPoint deck summarising key outputs, charts and strategic commentary (available as an add-on)
Built for strategic decision-makers in vaccines
This analysis is designed for organisations where competitive intelligence directly informs investment, licensing or development strategy.
Pharma & biotech BD
Licensing, partnering and portfolio gap analysis against a full industry landscape.
Strategy & corporate development
Investment thesis validation, competitive benchmarking, pipeline prioritisation.
R&D leadership
Platform positioning, pathogen prioritisation and white-space identification.
Investors & advisors
Evidence-based pipeline assessment for due diligence and sector positioning.
Government & procurement
Understanding the commercial pipeline landscape for procurement planning.
Market access & HEOR
Competitive context for payer submissions and value dossiers.
Analysis of the vaccine R&D pipeline is a critical component of any organisation's competitive intelligence effort - informing strategic portfolio management, business development, R&D prioritisation and corporate investment. The key challenge is that the pipeline is highly dynamic, and a historical view requires skilled judgement during curation, especially when assigning new analytical fields.
This November 2026 edition has been independently curated and annotated by VacZine Analytics, building on continuous pipeline coverage since 2007. The mRNA landscape focus section represents a significant new addition, reflecting the rapid maturation of mRNA technology beyond COVID-19 into influenza, RSV and oncology applications. It remains the only independently curated, industry-wide trial dataset of its kind available for licence.
License the Strategic Vaccine & mRNA Pipeline Review
Contact VacZine Analytics for pricing, sample worksheets and licensing terms. Single-licence and multi-user options available. Briefing call included on request.